Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | VDR | P11473 | 10/20 | 0.62 |
| ▸ | AR | P10275 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183068 | 0.91 | HDAC6 (0.68) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2969623 | 0.90 | HDAC6 (0.69) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL15076945 | 0.88 | HDAC6 (0.64) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL15076944 | 0.87 | HDAC6 (0.67) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL13203863 | 0.86 | HDAC6 (0.64) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2968315 | 0.86 | HDAC6 (0.64) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2963657 | 0.86 | HDAC6 (0.69) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL13203744 | 0.86 | HDAC6 (0.69) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL2949160 | 0.85 | VDR (0.75) | HDAC6HDAC3HDAC1VDRAR | |
| SCHEMBL16178208 | 0.84 | HDAC6 (0.59) | HDAC6HDAC3HDAC1VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794556-B1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | GLEASON JAMES L (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-2794556-B1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | GLEASON JAMES L (CA) | 2018-04-18 | — | — | EP | disclosed |
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| US-9428447-B2 | Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-08-30 | — | — | US | disclosed |
| EP-2794556-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | KALDRE, Dainis (CA) | 2014-10-23 | — | — | US | disclosed |
| WO-2013091082-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315965-A1 | BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER | VDR, CYP2R1, CYP24A1 | HDAC6 72/4885HDAC3 8/4885HDAC1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.